Natraj Proteins Ltd Downgraded to Sell Amid Mixed Financials and Weak Technicals

Quality Assessment: Weak Long-Term Fundamentals

From a quality perspective, Natraj Proteins continues to exhibit challenges. The company’s long-term fundamental strength remains weak, with a compounded annual growth rate (CAGR) in net sales of -7.11% over the past five years. This negative growth trend highlights persistent difficulties in expanding its revenue base in a competitive edible oil industry. Furthermore, the average return on equity (ROE) stands at a modest 6.97%, indicating limited profitability generated per unit of shareholders’ funds. Such a low ROE suggests that the company is not efficiently leveraging equity capital to generate returns, which is a concern for long-term investors seeking value creation.

In addition, Natraj Proteins has consistently underperformed against key benchmarks. Over the last three years, the stock has lagged behind the BSE500 index, with a one-year return of -15.69% compared to the benchmark’s -7.66%. The underperformance extends over longer horizons as well, with three- and five-year returns of -27.54% and -33.09% respectively, while the Sensex has delivered positive returns of 14.56% and 44.20% over the same periods. This persistent underperformance underscores the company’s struggle to keep pace with broader market gains.

Valuation: Attractive but Reflective of Risks

Despite the weak fundamentals, valuation metrics for Natraj Proteins present a more attractive picture. The company’s return on capital employed (ROCE) is reported at 1.0, which, combined with an enterprise value to capital employed ratio of 0.7, suggests the stock is trading at a discount relative to its peers’ historical valuations. This valuation discount may appeal to value investors looking for potential turnaround opportunities.

Moreover, the company’s price-to-earnings-to-growth (PEG) ratio is an exceptionally low 0.1, reflecting the stock’s depressed price relative to its earnings growth. Over the past year, while the stock price declined by 15.69%, profits surged by 178.1%, indicating a disconnect between market pricing and operational performance. This divergence could signal an undervaluation if the company sustains its profit growth trajectory.

Financial Trend: Mixed Signals with Recent Profit Growth

Financially, Natraj Proteins has demonstrated some encouraging signs in the most recent quarter (Q4 FY25-26). The company reported a profit after tax (PAT) of ₹1.11 crore, representing a remarkable growth of 244.2% compared to the previous four-quarter average. This surge in profitability is a positive development, suggesting operational improvements or cost efficiencies that have begun to materialise.

However, the broader financial trend remains subdued. The company’s net sales have declined over the last five years, and its average ROE remains low. While the recent quarterly profit growth is promising, it has yet to translate into sustained top-line expansion or improved returns on equity. Investors should weigh this short-term financial improvement against the longer-term trend of underperformance and weak fundamentals.

Technical Analysis: Downgrade Driven by Weakening Momentum

The primary catalyst for the downgrade to a Sell rating is the deterioration in technical indicators. The technical grade for Natraj Proteins has shifted from mildly bullish to sideways, signalling a loss of upward momentum in the stock price. This shift is reflected in several key technical metrics:

• MACD: Weekly readings have turned mildly bearish, while monthly readings remain mildly bullish, indicating mixed momentum but a recent weakening trend.
• RSI: Both weekly and monthly relative strength index (RSI) readings show no clear signal, suggesting a lack of strong directional momentum.
• Bollinger Bands: Both weekly and monthly bands are bearish, implying increased volatility with downward pressure on the stock price.
• Moving Averages: Daily moving averages remain mildly bullish, but this is insufficient to offset the broader bearish signals.
• KST Indicator: Weekly readings are mildly bearish and monthly readings bearish, reinforcing the negative momentum.
• Dow Theory: Weekly charts show no clear trend, while monthly charts are mildly bullish, indicating uncertainty in trend direction.

These technical signals collectively point to a weakening price trend. The stock closed at ₹36.00 on 24 July 2026, down 6.25% from the previous close of ₹38.40, and remains below its 52-week high of ₹47.90. The daily trading range between ₹35.05 and ₹36.15 further reflects volatility and investor caution.

Comparative Performance and Market Context

When compared to the broader market, Natraj Proteins’ returns have been lacklustre. Year-to-date, the stock has delivered a 12.50% return, outperforming the Sensex’s -10.36% return. However, this short-term outperformance is overshadowed by the one-year and longer-term underperformance. Over one year, the stock’s -15.69% return lags the Sensex’s -7.66%, and over five and ten years, the stock’s returns of -33.09% and 27.43% pale in comparison to the Sensex’s 44.20% and 174.76% respectively.

Majority shareholding remains with non-institutional investors, which may contribute to lower liquidity and higher volatility. The company operates in the refined oil and vanaspati segment, a competitive and price-sensitive industry where operational efficiencies and scale are critical for sustained growth.

Summary and Outlook for Investors

The downgrade of Natraj Proteins Ltd to a Sell rating by MarketsMOJO reflects a comprehensive evaluation of multiple factors. While the company has shown encouraging profit growth in the latest quarter and trades at an attractive valuation relative to peers, its weak long-term sales growth, low profitability ratios, and persistent underperformance against benchmarks weigh heavily on its investment appeal.

Most notably, the shift in technical indicators from mildly bullish to sideways and bearish signals across key momentum measures has triggered caution. The stock’s recent price decline and volatility suggest that market sentiment is turning negative, which could limit near-term upside potential.

Investors should carefully consider these mixed signals. The company’s micro-cap status and majority non-institutional ownership add layers of risk, including liquidity constraints and higher price swings. While the valuation discount and recent profit surge offer some hope for a turnaround, the overall assessment advises prudence.

For those currently holding Natraj Proteins, it may be prudent to reassess portfolio allocations in light of the downgrade and explore alternative investments within the edible oil sector or broader market that demonstrate stronger fundamentals and technical momentum.

About the Rating Change

MarketsMOJO’s rating downgrade from Hold to Sell on 23 July 2026 is based on a comprehensive analysis of four key parameters:

• Quality: Downgraded due to weak long-term sales growth and low average ROE of 6.97%.
• Valuation: Remains attractive with EV/Capital Employed at 0.7 and PEG ratio of 0.1, reflecting undervaluation.
• Financial Trend: Mixed, with strong recent quarterly PAT growth of 244.2% but negative five-year sales CAGR.
• Technicals: Downgraded from mildly bullish to sideways, with bearish signals from MACD, Bollinger Bands, and KST indicators.

This multi-dimensional approach ensures investors receive a balanced view of the company’s prospects and risks.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today